Lilly and Boehringer eye FDA nod for diabetes combo; White House halts infectious disease studies;

@FierceBiotech: Great panel with $BLUE, $PFE, $AGIO, $GSK and $SNY on the revolution in drug R&D. Video will be up on site tomorrow. | Follow @FierceBiotech

@JohnCFierce: Top 10 Phase III disasters of 2014. Feature | Follow @JohnCFierce

@DamianFierce: RT @DatamonitorMark: David Shlaes: "AZ has told its antibiotics researchers they should make efforts to find other jobs in near future." Blog post via Antibiotics - The Perfect Storm | Follow @DamianFierce

@EmilyMFierce: Human intestinal organoids grown in mice could help personalize treatments. FierceBiotech Research story | Follow @EmilyMFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim are nearing another approval in their long-standing diabetes alliance, as the FDA has accepted their application for a fixed-dose combination of empagliflozin and metformin. Empagliflozin, an SGLT-2 inhibitor, won FDA approval in August and is marketed as Jardiance. News

> The White House has halted funding for so-called gain-of-function studies of infectious diseases like MRSA and SARS, weighing whether such research, in which scientists make viruses more dangerous, are too risky. Story

> The FDA signed off on RegeneRx's plans to resume a Phase III study on RGN-259, an eye drop for the orphan corneal disease neurotrophic keratopathy. More

Medical Device News

@FierceMedDev: 2014's most memorable medtech patent battles. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Nanodevices could be unleashed by DNA-brick self-assembly. Article | Follow @VarunSaxena2

@EmilyWFierce: RIP Shabbvie. Bloomberg piece | Follow @EmilyWFierce

> Illumina up 10% on strongest growth since 2011, raises 2014 guidance. Story

> Google, KKR, Kleiner Perkins invest $542M in virtual reality eyeglass startup. Article

> FDA clears app to monitor brain health on the battlefield. More

> Q&A: CMO says Covidien wants to engage parallel review process. Editor's Corner

Pharma News

@FiercePharma: Actavis, Sanofi, Boehringer jockey bids for OTC specialist Omega Pharma. Report | Follow @FiercePharma

@EricPFierce: Top-read special report Monday: The top 10 most expensive drugs of 2013. Feature | Follow @EricPFierce

@CarlyHFierce: Novartis recruits Nick Cannon for double-whammy flu campaign. FiercePharmaMarketing story | Follow @CarlyHFierce

> AbbVie faces stumbling blocks after cutting cord on $55B Shire deal. Article

> Top investor bails on Valeant bid, backing Allergan-Shire combo instead. Report

> It's back to basics in M&A, and that's a good thing, Actelion CEO says. More

Biotech Research News

> GlaxoSmithKline drug flips off cancer mechanism in aggressive leukemia. Story

> Protein boost restores hearing in deaf mice. More

> Human intestinal organoids grown in mice could help personalize treatments. Story

> Researchers pinpoint potent anti-obesity compounds. More

> Protein switch could boost recovery after heart attack. Article

Pharma Manufacturing News

> Janssen recalls 13,500 bottles of Xarelto because of contamination. News

> Canada cuts Apotex a break on some banned drugs. Report

> BARDA calls on Novartis, GSK, Emergent to pitch in with Ebola drug. Article

> FDA will start the new year with its Office of Quality in place. Item

> Lilly closing 1 Puerto Rico plant next year but investing in another. More

Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.